The safety and efficacy of adding total ablative therapy of all disease sites to standard systemic treatment is being investigated in patients with limited metastatic colorectal cancer as part of the ongoing phase 3 ERASur study.
Kathryn Hitchcock, MD, PhD, discusses the rationale for the ongoing phase 3 ERAsur trial investigating total ablative therapy in patients with limited metastatic colorectal cancer and details the methodologies being used in this study.